The primary objective of the study is to evaluate the efficacy and safety of goflikicept (GFC) and olokizumab (OKZ) in patients with Still's disease
Voluntarily signed and dated Informed Consent Form (ICF) of the patient agreed to take part in this Study
Confirmed diagnosis of Adult-Onset Still's Disease (AOSD) based on the Yamaguchi M. diagnostic criteria
Patient with active disease or low disease activity per DAVID criteria
In case of current corticosteroid (CS) use, doses must be stable for at least 2 weeks prior to Day 0. The maximum allowed dose of CS is 1 mg/kg/day, up to 60 mg/day (prednisolone equivalent)
Hypersensitivity to the active and/or inactive ingredients of the investigational product
Rilonacept - less than 6 weeks prior to Day 0
Canakinumab - less than 20 weeks prior to Day 0
Anakinra - less than 1 week prior to Day 0